Literature DB >> 7982186

One hundred neuroblastomas detected through a mass screening system in Japan.

Y Hachitanda1, K Ishimoto, J Hata, H Shimada.   

Abstract

BACKGROUND: In Japan, a nationwide mass screening (MS) program for preclinical detection of neuroblastoma in infants was done by measuring urinary vanillylmandelic acid and homovanillic acid at the age of 6 months. In this study, clinical, histopathologic, and biologic features of 100 neuroblastomas detected through the Japanese MS are presented.
METHODS: Clinical data of the MS cases were collected and histologic and biologic studies performed on the surgically resected neuroblastomas. Histopathologic evaluation was done including the Shimada classification (all tumors), N-myc oncogene status (58 tumors), and ploidy analysis (31 tumors). The serum ferritin level was measured before surgical intervention in 27 cases.
RESULTS: The primary tumor sites of these cases were adrenal (69), retroperitoneum (21), and mediastinum (10). The tumors were clinical Stage I (31), II (31), III (19), IV (8), and IV-S (9); two children had bilateral primary adrenal tumors. Ninety-three percent (93/100) had favorable histology; 100% (58/58) had nonamplified N-myc oncogene expression; 81% (25/31) showed a favorable ploidy pattern, and 96% (26/27) had normal serum ferritin levels. To date, all children in this series are alive and well, although a total of 13 tumors were associated with one or two poor risk factors; 6 had unfavorable histology (UH), 5 had an unfavorable ploidy (UP) pattern, one had UH and UP, and one had an elevated ferritin level.
CONCLUSIONS: The majority of neuroblastomas detected through the MS showed favorable biologic factors (biologically favorable group). However, there was a small group with histopathologic and/or biologic unfavorable factors. Patients with unfavorable factors apparently benefit most from early surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982186     DOI: 10.1002/1097-0142(19941215)74:12<3223::aid-cncr2820741222>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Disseminated neuroblastomas under 1 year of age: cell biology and prognosis.

Authors:  F Lampert; H Christiansen; F Berner; H J Terpe; F Berthold
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 2.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

3.  Successful treatment of infants with localized neuroblastoma based on their MYCN status.

Authors:  Tomoko Iehara; Minoru Hamazaki; Tatsuro Tajiri; Yoshifumi Kawano; Michio Kaneko; Hitoshi Ikeda; Hajime Hosoi; Tohru Sugimoto; Tadashi Sawada
Journal:  Int J Clin Oncol       Date:  2012-03-02       Impact factor: 3.402

Review 4.  Gene profiling of high risk neuroblastoma.

Authors:  Sanjeev A Vasudevan; Jed G Nuchtern; Jason M Shohet
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

Review 5.  The epidemiology of neonatal tumours. Report of an international working group.

Authors:  S W Moore; D Satgé; A J Sasco; A Zimmermann; J Plaschkes
Journal:  Pediatr Surg Int       Date:  2003-09-11       Impact factor: 1.827

6.  MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.

Authors:  T Iehara; H Hosoi; K Akazawa; Y Matsumoto; K Yamamoto; S Suita; T Tajiri; T Kusafuka; E Hiyama; M Kaneko; F Sasaki; T Sugimoto; T Sawada
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.